RHJA
MIRM icon

Rice Hall James & Associates’s Mirum Pharmaceuticals MIRM Stock Holding History

Rice Hall James & Associates’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13M Sell
110,673
-36,364
-25% -$3.65M 0.63% 50
2026
Q1 		$13.6M Sell
147,037
-17,412
-11% -$1.64M 0.76% 43
2025
Q4 		$13M Sell
164,449
-297
-0.2% -$21.3K 0.72% 45
2025
Q3 		$12.1M Sell
164,746
-67,247
-29% -$4.27M 0.66% 47
2025
Q2 		$11.8M Sell
231,993
-2,703
-1% -$120K 0.64% 46
2025
Q1 		$10.6M Sell
234,696
-4,303
-2% -$203K 0.62% 47
2024
Q4 		$9.88M Sell
238,999
-3,712
-2% -$155K 0.54% 54
2024
Q3 		$9.47M Buy
242,711
+12,981
+6% +$518K 0.51% 54
2024
Q2 		$7.85M Buy
229,730
+14,843
+7% +$389K 0.47% 58
2024
Q1 		$5.4M Buy
214,887
+172,047
+402% +$4.73M 0.31% 71
2023
Q4 		$1.26M Sell
42,840
-10,539
-20% -$319K 0.07% 207
2023
Q3 		$1.69M Sell
53,379
-1,075
-2% -$29.4K 0.11% 182
2023
Q2 		$1.41M Buy
54,454
+2,159
+4% +$57.4K 0.08% 196
2023
Q1 		$1.26M Buy
+52,295
New +$1.19M 0.07% 229

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Rice Hall James & Associates's MIRM Position: Q2 2026 in Review

Rice Hall James & Associates reduced its Mirum Pharmaceuticals (MIRM) stake by 25% in Q2 2026, selling an estimated $3.65M and leaving 110,673 shares worth $13M. The position accounts for 0.63% of the portfolio, ranked #50.

Rice Hall James & Associates first reported a position in MIRM in Q1 2023 and has held it in 14 quarters since. The position peaked at $13.6M in Q1 2026. 327 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

  • Rice Hall James & Associates held 110,673 shares of Mirum Pharmaceuticals worth $13M as of Q2 2026.
  • Rice Hall James & Associates sold 36,364 Mirum Pharmaceuticals shares in Q2 2026, an estimated $3.65M.
  • Mirum Pharmaceuticals made up 0.63% of Rice Hall James & Associates's portfolio in Q2 2026, its #50 holding.
  • Rice Hall James & Associates first reported a position in Mirum Pharmaceuticals in Q1 2023 and has held it in 14 quarters since.
  • Rice Hall James & Associates's Mirum Pharmaceuticals position peaked at $13.6M in Q1 2026.
  • 327 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on Rice Hall James & Associates's 13F filing for Q2 2026, filed 7 Aug 2026.